NEP

In mice, withdrawal from repeated NEP administration produces increased aggressive behavior, persistently impaired social exploration, and abolition of the anxiolytic effect observed during acute exposuresupported

Acute: anxiolytic effects. Withdrawal: increased aggression, persistently impaired social exploration. j.pnpbp.2022.110562

The most detailed acute toxicity data derive from the Belgian case report: a male patient developed severe agitation, delusions of persecution, tachycardia, mydriasis, and fever following intranasal NEP administration, progressing to rhabdomyolysis, acute renal failure, metabolic acidosis, and coma requiring ICU admission and mechanical ventilation for three dayssupported

male patient snorted NEP, admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever; developed renal failure, rhabdomyolysis, metabolic acidosis, coma. Intubated 3 days. bkac092

Complete recovery was achieved with supportive care.supported

Recovery complete. bkac092

In mice, NEP produces slight hyperthermia at 10 mg/kg (i.p.) and reduced weight gain with repeated dosing.supported

Acute: slight hyperthermia. Withdrawal: reduced weight gain. j.pnpbp.2022.110562

Tachycardia is confirmed in clinical case reportssupported

admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever. bkac092

Rhabdomyolysis and acute renal failure are documented as NEP-attributable sequelae in a single case reportsupported

developed renal failure, rhabdomyolysis, metabolic acidosis, coma. bkac092

Fever is documented in the clinical case, and slight hyperthermia occurs in mice at 10 mg/kg.supported

admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever. bkac092

Fever is documented in the clinical case, and slight hyperthermia occurs in mice at 10 mg/kg.supported

Acute: anxiolytic effects, reduced social exploration, slight hyperthermia. j.pnpbp.2022.110562

NEP was detected in blood samples from 26 fatal and 2 non-fatal poisoning cases in Polandsupported

26 fatal and 2 non-fatal cases with synthetic cathinones in Poland. NEP among most commonly detected. bkab119

In a broader forensic series of 96 NPS-related fatalities, synthetic cathinones were detected in 67% of cases, with alcohol co-detected in 27 cases (blood alcohol 0.6–3.6‰).supported

96 NPS-related fatalities from forensic practice 2010-2023. Synthetic cathinones in 67% of cases. Ethanol co-detected in 27 cases (0.6-3.6‰). j.forsciint.2024.112204

Management is supportive, extrapolated from cocaine and amphetamine overdose protocolssupported

No specific antidote; management extrapolated from cocaine/amphetamines. sar.s37257

Claim in safety — inconclusiveinconclusiveworking →

Acute psychological adverse effects documented in case reports include severe agitation, delusions of persecution, and paranoiasupported

admitted with severe agitation, delusions of persecution. bkac092

In the overdose context described by Deville et al., the patient exhibited persecutory delusions before progressing to coma.supported

admitted with severe agitation, delusions of persecution... coma. bkac092

Repeated NEP administration in mice (twice daily for 5 days) produces robust striatal ΔFosB accumulation — the most reliable molecular marker of addiction vulnerability — alongside decreased striatal dopamine and elevated corticosterone during withdrawalsupported

repeatedly (twice/day, 5 days). Withdrawal: elevated corticosterone, decreased striatal dopamine. Robust ΔFosB increase in striatum suggests high dependence risk. j.pnpbp.2022.110562

The structural precursor pentedrone maintains self-administration in rats at 0.3 mg/kg/infusion and produces conditioned place preference at 3–10 mg/kg.supported

self-administration (0.3 mg/kg/infusion) in rodents. Conditioned place preference (3, 10 mg/kg). adb.12299

Claim in safety — inconclusiveinconclusiveworking →

DAT-predominant cathinones carry the highest addiction liability among the three cathinone pharmacological groupssupported

Dopaminergic drugs highly addictive; toxicity includes prolonged stimulation, insomnia, agitation, psychosis. s00204-020-02693-7

Claim in safety — inconclusiveinconclusiveworking →

Approximately 95% of synthetic cathinone users co-use alcoholsupported

~95% of cathinone consumers combine with alcohol. j.taap.2015.12.019

In adolescent mice, the ethanol-mephedrone combination potentiates neurotoxicity approximately 2-fold compared to either substance alonesupported

Mephedrone + ethanol combination in mice: 2-fold increase in neurotoxicity markers. j.taap.2015.12.019

In the forensic series reported by Rojek et al., alcohol was co-detected in 27 of 96 NPS-related fatalities (blood alcohol 0.6–3.6‰)supported

Ethanol co-detected in 27 cases (0.6-3.6‰). j.forsciint.2024.112204

NEP's CYP metabolism profile has not been characterizedsupported

20 metabolites identified via hepatocyte incubation; 18 confirmed in authentic human urine. Major pathways: N-deethylation, carbonyl reduction. j.jpba.2025.117170

Cardiovascular disease (hypertension, coronary artery disease, arrhythmias, structural heart disease) represents an absolute contraindication given the confirmed tachycardia and expected noradrenergic-mediated cardiovascular stresssupported

admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever. bkac092

Renal impairment constitutes a relative contraindication in light of the documented rhabdomyolysis and acute renal failure.supported

developed renal failure, rhabdomyolysis, metabolic acidosis, coma. bkac092

Psychotic disorders and bipolar disorder represent relative contraindications, as dopaminergic stimulation may precipitate or exacerbate psychotic episodes — a risk supported by the persecutory delusions documented in the overdose casesupported

admitted with severe agitation, delusions of persecution. bkac092

The only controlled human administration of NEP appears in Massano et al., where volunteers received 20–40 mg intranasally or orally as part of a metabolic profiling studysupported

Human volunteers administered 20-40 mg NEP intranasally or orally. j.jpba.2024.115994

Claim in clinical-evidence — inconclusiveinconclusiveworking →

Pieprzyca et al. identified NEP among the most frequently detected synthetic cathinones in blood samples from a series of 26 fatal and 2 non-fatal poisoning casessupported

26 fatal and 2 non-fatal cases with synthetic cathinones in Poland. NEP among most commonly detected. bkab119

Rojek et al. analyzed 96 NPS-related fatalities from 2010–2023, finding synthetic cathinones in 67% of casessupported

96 NPS-related fatalities from forensic practice 2010-2023. Synthetic cathinones in 67% of cases. j.forsciint.2024.112204

In drug discrimination assays, NEP fully substituted for both cocaine (10 mg/kg) and methamphetamine (1 mg/kg) discriminative stimulus cues in rats.supported

NEP fully substituted for cocaine and methamphetamine discriminative cues. j.pbb.2025.174100

Espinosa-Velasco et al. investigated acute and repeated NEP exposure in male OF1 mice (i.p. 1, 3, 10 mg/kg, twice daily for 5 days)supported

Male OF1 mice treated acutely (1,3,10 mg/kg i.p.) and repeatedly (twice/day, 5 days) with NEPD. j.pnpbp.2022.110562

Neurochemically, withdrawal was associated with increased plasma corticosterone, decreased striatal dopamine, and robust long-lasting ΔFosB accumulation in the striatum.supported

Withdrawal: elevated corticosterone, decreased striatal dopamine. Robust ΔFosB increase in striatum suggests high dependence risk. j.pnpbp.2022.110562

Deville et al. reported a male patient presenting to the emergency department following intranasal NEP use with severe agitation, delusions of persecution, tachycardia, mydriasis, and feversupported

male patient snorted NEP, admitted with severe agitation, delusions of persecution, tachycardia, mydriasis, fever. bkac092

Drevin et al. reported NEP detection in the plasma and urine of a 36-year-old male victim of drug-facilitated sexual assault, confirmed by LC-HRMSsupported

NEPD detected in plasma and urine of 36-year-old male victim of DFSA via LC-HRMS. j.forsciint.2024.112030

The authors note that NEP's limited entactogenic properties relative to methylone or mephedrone position it as more relevant to chemsex contexts than to classical DFSA scenarios, though the case demonstrates the potential for non-consensual administration.supported

only small minority of users report entactogenic effects. NEPD more suitable for chemsex than DFSA context. j.forsciint.2024.112030

The study provides pioneering blood concentration data for NEP in poisoning contexts.supported

Presents pioneering blood concentration data for NEP. bkab119

Alcohol was co-detected in 27 cases (blood alcohol 0.6–3.6‰), and co-use with opioids and benzodiazepines was common.partially supported

Ethanol co-detected in 27 cases (0.6-3.6‰). 37 NPS and 9 metabolites detected. j.forsciint.2024.112204

Pentedrone (N-methylpentedrone) — differs from NEP only by a single methyl-to-ethyl substitution at the terminal amine. Simmler et al. characterized pentedrone as a non-releasing NE and DA uptake inhibitor in HEK-293 cells expressing human monoamine transporters.supported

Pentedrone (NEP's parent compound) characterized as non-releasing NE and DA uptake inhibitor at human transporters. j.neuropharm.2013.11.008

N-Ethylhexedrone (NEH) — one additional α-chain carbon relative to NEP. Kolaczynska et al. reported DAT IC₅₀ = 0.17 µM and NET IC₅₀ = 0.18 µM in human transporter-expressing HEK-293 cells, with no SERT activity at concentrations below 10 µM (DAT/SERT selectivity ratio = 264–356). No compounds in the series induced monoamine efflux.supported

NEH shows DAT IC50=0.17µM, NET IC50=0.18µM, >10µM at SERT. DAT/SERT ratio=264-356 for NEH. None induce monoamine efflux. ijms22158277

Within the three-group pharmacological classification of designer cathinones established by Simmler et al. — (1) non-selective monoamine uptake inhibitors (cocaine-like), (2) preferential DA/NE releasers (amphetamine-like), and (3) highly potent selective DAT/NET inhibitors without releasing activity (pyrovalerone-like) — NEP falls into Group 3 by structural and functional analogysupported

Landmark paper: pharmacological classification of cathinones into three groups based on DAT/SERT selectivity and releasing vs inhibiting mechanism. Pyrovalerone and MDPV identified as highly potent selective DAT/NET transporter inhibitors without releasing activity. j.1476-5381.2012.02145.x

This classification predicts strong dopaminergic stimulant effects and elevated addiction liability relative to SERT-active cathinones.supported

Dopaminergic drugs highly addictive; toxicity includes prolonged stimulation, insomnia, agitation, psychosis. s00204-020-02693-7

Fitzgerald et al. demonstrated that N-ethyl substitution on cathinone backbones augments relative SERT potency compared to N-methyl while reducing NET/DAT releasing effects — consistent with NEP's non-releasing NDRI profile.supported

Para-chloro substitution or increased N-alkyl chain length augmented SERT potency. Combined para-chloro + N-ethyl substitutions reduced releasing at NET/DAT. j.neuropharm.2023.109827

Daziani et al. identified the primary metabolic pathways of NEP in human urine and hepatocyte incubations: N-deethylation constitutes the dominant route, with carbonyl reduction as a secondary pathwaysupported

Major pathways: N-deethylation, carbonyl reduction, and their combination. j.jpba.2025.117170

Massano et al. confirmed the urinary metabolic profile following administration of 20–40 mg NEP (intranasal or oral) to human volunteers, identifying key metabolites via UHPLC-QTOF-HRMS.supported

Human volunteers administered 20-40 mg NEP intranasally or orally. Phase-I and glucuronide (phase-II) metabolites identified. j.jpba.2024.115994

The Belgian case report by Deville et al. documents blood NEP concentrations exceeding 2,000 ng/mL with no measurable decline over a 17-hour observation window following intranasal administration — the only published quantitative plasma persistence datasupported

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life. bkac092

NEP shares the metabolite 2-amino-1-phenylpentan-1-ol with pentedrone and α-PVP, creating analytical challenges for anti-doping testingsupported

Metabolite 2-amino-1-phenylpentan-1-ol identified in anti-doping sample; shared by pentedrone, α-PVP, and NEP. Highlights analytical challenges with NPS in doping control. dta.70047

Standard clinical immunoassays (EMIT-type amphetamine and MDMA screens) show poor cross-reactivity with synthetic cathinones including NEP, producing frequent false negativessupported

SCs can produce false positives on MDMA and amphetamine immunoassays but may be missed by standard screening. 00045632251331404

Confirmatory identification requires LC-MS/MS or UHPLC-QTOF-HRMS methodology.supported

Metabolic profile of N-ethylhexedrone, N-ethylpentedrone, and 4-chloromethcathinone in urine samples by UHPLC-QTOF-HRMS. j.jpba.2024.115994

Claim in pharmacology — inconclusiveinconclusiveworking →

Espinosa-Velasco et al. demonstrated that repeated NEP administration (1, 3, or 10 mg/kg i.p., twice daily for 5 days) in mice produces robust and long-lasting ΔFosB accumulation in the striatum. ΔFosB is a truncated splice variant of the FosB transcription factor that accumulates with chronic drug exposure and persists for weeks after cessationsupported

Male OF1 mice treated acutely (1,3,10 mg/kg i.p.) and repeatedly (twice/day, 5 days) with NEPD. Robust ΔFosB increase in striatum suggests high dependence risk. j.pnpbp.2022.110562

The same study documented decreased striatal dopamine during withdrawal from repeated NEP administrationsupported

Withdrawal: decreased striatal dopamine. j.pnpbp.2022.110562

Plasma corticosterone was elevated during NEP withdrawal in mice, indicating hypothalamic-pituitary-adrenal (HPA) axis activationsupported

Withdrawal: elevated corticosterone. j.pnpbp.2022.110562

Acute NEP administration produced dose-dependent locomotor stimulation, anxiolytic effects, reduced social exploration, slight hyperthermia (at 10 mg/kg), and reduced weight gain in micepartially supported

Acute: anxiolytic effects, reduced social exploration, slight hyperthermia. Withdrawal: increased aggression, persistently impaired social exploration, increased locomotor activity, reduced weight gain. j.pnpbp.2022.110562

During withdrawal, the anxiolytic effect was abolished, social exploration remained impaired, aggressive behavior increased, and locomotor activity was elevated — a behavioral profile consistent with dopaminergic sensitization and noradrenergic dysregulation.supported

Withdrawal: increased aggression, persistently impaired social exploration, increased locomotor activity. j.pnpbp.2022.110562

In the Espinosa-Velasco data, the increased locomotor activity during withdrawal from repeated NEP likely reflects locomotor sensitizationsupported

Withdrawal: increased locomotor activity. j.pnpbp.2022.110562

Does NEP's prolonged plasma persistence (>17 hours at >2,000 ng/mL in one case) reflect slow metabolism, extensive tissue distribution, or continued absorption? This question is critical for overdose management.supported

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life. bkac092

By blocking dopamine reuptake at presynaptic DAT terminals, NEP prolongs dopaminergic signaling in the NAc, producing the euphoric and motivational effects characteristic of psychostimulants.supported

Cathinones/stimulants: primarily interact with monoamine transporters. Dopaminergic drugs highly addictive. s00204-020-02693-7

By blocking dopamine reuptake at presynaptic DAT terminals, NEP prolongs dopaminergic signaling in the NAc, producing the euphoric and motivational effects characteristic of psychostimulants.supported

Mechanism: catecholamine release/reuptake inhibition. Desired effects: increased energy, empathy, libido. sar.s37257

Massano et al. administered 20–40 mg NEP intranasally or orally to human volunteers for metabolic profiling purposes; pharmacokinetic parameters (Tmax, Cmax, AUC) were not reported as study endpointssupported

Human volunteers administered 20-40 mg NEP intranasally or orally. Phase-I and glucuronide (phase-II) metabolites identified. j.jpba.2024.115994

Urinary metabolites are detectable by UHPLC-QTOF-HRMS following doses of 20–40 mgsupported

Human volunteers administered 20-40 mg NEP intranasally or orally. Phase-I and glucuronide (phase-II) metabolites identified. Urine collected 0-5h post-administration. j.jpba.2024.115994

These pathways were characterized in both authentic human urine samples and in vitro human hepatocyte incubations, with good concordance between the two systems. In silico metabolite prediction also demonstrated agreement with experimental findings.supported

20 metabolites identified via hepatocyte incubation; 18 confirmed in authentic human urine. j.jpba.2025.117170

These pathways were characterized in both authentic human urine samples and in vitro human hepatocyte incubations, with good concordance between the two systems. In silico metabolite prediction also demonstrated agreement with experimental findings.supported

20 metabolites identified via hepatocyte incubation; 18 confirmed in authentic human urine. j.jpba.2025.117170

The sole published plasma persistence data derive from a case of severe intoxication: blood NEP concentrations exceeded 2,000 ng/mL with no measurable decrease over 17 hours of monitoring following intranasal administrationsupported

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life. bkac092

Enantioselective analysis of NEP and metabolites in oral fluid and urine has been demonstrated using SFC-MS/MS.supported

SFC-MS/MS method for enantioselective separation and detection of NEP and major phase-1 metabolites in human oral fluid and urine. j.jpba.2026.117474

<div class="compact-kv"> <table> <tbody> <tr><td>Oral bioavailability</td><td>Not determined</td></tr> <tr><td>Tmax</td><td>Not determined</td></tr> <tr><td>Elimination half-life</td><td>Not determined (>17 h implied by case data)</td></tr> <tr><td>Volume of distribution</td><td>Not determined</td></tr> <tr><td>Protein binding</td><td>Not determined</td></tr> <tr><td>Primary metabolism</td><td>N-deethylation, carbonyl reduction</td></tr> <tr><td>CYP enzymes</td><td>Not characterized (CYP2D6, CYP3A4 suspected)</td></tr> <tr><td>Active metabolites</td><td>Not determined</td></tr> </tbody> </table> </div>supported

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life. bkac092

Case data suggest a prolonged pharmacokinetic profile, with plasma concentrations exceeding 2,000 ng/mL showing no decline over 17 hours following intranasal administration.supported

Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life. bkac092

A DEA-commissioned behavioral study classified NEP as producing psychostimulant effects with abuse liability comparable to cocaine and methamphetaminesupported

NEP fully substituted for cocaine and methamphetamine discriminative cues. Suggests high abuse liability similar to cocaine/methamphetamine. j.pbb.2025.174100

NEP is presumed to act as a non-releasing norepinephrine-dopamine reuptake inhibitor (NDRI) based on structural analogy with pentedrone and N-ethylhexedrone (DAT IC₅₀ = 0.17 µM, NET IC₅₀ = 0.18 µM, negligible SERT activity)supported

Pentedrone (NEP's parent compound) characterized as non-releasing NE and DA uptake inhibitor at human transporters. j.neuropharm.2013.11.008

NEP is presumed to act as a non-releasing norepinephrine-dopamine reuptake inhibitor (NDRI) based on structural analogy with pentedrone and N-ethylhexedrone (DAT IC₅₀ = 0.17 µM, NET IC₅₀ = 0.18 µM, negligible SERT activity)supported

NEH (N-ethylhexedrone, one-carbon homolog of NEP) shows DAT IC50=0.17µM, NET IC50=0.18µM, >10µM at SERT. None induce monoamine efflux. ijms22158277

The resulting pharmacological profile predicts cocaine-like sympathomimetic stimulation — tachycardia, mydriasis, psychomotor activation, appetite suppression — with minimal entactogenic or serotonergic charactersupported

only small minority of users report entactogenic effects. j.forsciint.2024.112030

A single case report documents rhabdomyolysis, acute renal failure, metabolic acidosis, and coma as sole-substance sequelae of intranasal NEPsupported

male patient snorted NEP... developed renal failure, rhabdomyolysis, metabolic acidosis, coma. bkac092

Repeated administration in mice produces robust striatal ΔFosB accumulation and decreased dopamine during withdrawal — molecular signatures predicting high dependence liabilitysupported

Robust ΔFosB increase in striatum suggests high dependence risk. Withdrawal: decreased striatal dopamine. j.pnpbp.2022.110562

In drug discrimination assays, NEP fully substituted for both cocaine (10 mg/kg) and methamphetamine (1 mg/kg) discriminative stimulus cues in rats, confirming functional overlap with both reference stimulants.supported

NEP fully substituted for cocaine and methamphetamine discriminative cues. Suggests high abuse liability similar to cocaine/methamphetamine. j.pbb.2025.174100

The structural precursor pentedrone maintains responding in self-administration paradigms and produces conditioned place preference at 3 and 10 mg/kg in ratssupported

Pentedrone (NEP parent compound) shows rewarding properties in conditioned place preference (3, 10 mg/kg) and self-administration (0.3 mg/kg/infusion) in rodents. adb.12299

Gatch et al. directly compared locomotor stimulant effects of NEP against four other synthetic cathinones in micesupported

DEA-identified cathinones including NEP tested in mice/rats. Rank order potency: 4-MEAP > NEP > N-ethylheptedrone > 4-methylpentedrone. j.pbb.2025.174100

Only a small minority of users report mild MDMA-like effectssupported

only small minority of users report entactogenic effects. j.forsciint.2024.112030

This pharmacological distinction has practical implications: NEP produces a dopaminergic stimulant experience that is mechanistically more comparable to cocaine than to mephedrone.supported

Pyrovalerone and MDPV identified as highly potent selective DAT/NET transporter inhibitors without releasing activity. j.1476-5381.2012.02145.x

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

NEP has also appeared in chemsex settings, where its stimulant profile without entactogenic properties positions it distinctly among synthetic cathinones.supported

NEPD more suitable for chemsex than DFSA context. Only small minority of users report entactogenic effects. j.forsciint.2024.112030

By 2022, NEP had emerged among the most frequently detected synthetic cathinones in fatal poisoning cases in Poland, where a forensic toxicological analysis identified it in blood samples from 26 fatal and 2 non-fatal casessupported

26 fatal and 2 non-fatal cases with synthetic cathinones in Poland. NEP among most commonly detected. bkab119

Case reports from 2023–2024 documented severe ICU-level toxicity in Belgium and use in a drug-facilitated sexual assault context in Francesupported

Intubated 3 days. Blood NEP >2000 ng/mL with no decrease over 17h — consistent with long half-life. Recovery complete. bkac092

Case reports from 2023–2024 documented severe ICU-level toxicity in Belgium and use in a drug-facilitated sexual assault context in Francesupported

NEPD detected in plasma and urine of 36-year-old male victim of DFSA via LC-HRMS. j.forsciint.2024.112030

Claim in history — not_supportednot supportedworking →

Claim in history — not_supportednot supportedworking →

Structure-activity relationship analyses identify the size of the N-alkyl substituent and the α-chain length as the principal determinants of transporter selectivity and releasing vs. inhibiting mechanism in this series.supported

Key structural features: nature of terminal amine, size of alpha-substituent, stereochemistry. These features determine whether compound acts as releasing agent or reuptake inhibitor, and transporter selectivity. 7854_2016_41

Structure-activity relationship analyses identify the size of the N-alkyl substituent and the α-chain length as the principal determinants of transporter selectivity and releasing vs. inhibiting mechanism in this series.supported

Extension of alkyl chain enhances NET/DAT inhibition potency. ijms22158277

Cathinone derivatives including NEP exhibit chemical and stereochemical instability, particularly at elevated pHsupported

Demonstrates stereochemical instability at high pH. j.jpba.2026.117474

An SFC-MS/MS method provides efficient chiral separation of both enantiomers and their polar metabolites in oral fluid and urine matricessupported

SFC-MS/MS method for enantioselective separation and detection of NEP and major phase-1 metabolites in human oral fluid and urine. j.jpba.2026.117474

Claim in chemistry — not_supportednot supportedworking →

NEP's position between pentedrone and NEH in α-chain length, combined with its shared N-ethyl substituent with NEH, predicts a DAT/NET inhibition profile of comparable or slightly lower potency than NEH (IC₅₀ values in the low-to-sub-micromolar range) with negligible SERT activity.supported

NEH shows DAT IC50=0.17µM, NET IC50=0.18µM, >10µM at SERT. Extension of alkyl chain enhances NET/DAT inhibition potency. ijms22158277

NEP's position between pentedrone and NEH in α-chain length, combined with its shared N-ethyl substituent with NEH, predicts a DAT/NET inhibition profile of comparable or slightly lower potency than NEH (IC₅₀ values in the low-to-sub-micromolar range) with negligible SERT activity.supported

Pentedrone (NEP's parent compound) characterized as non-releasing NE and DA uptake inhibitor at human transporters. j.neuropharm.2013.11.008

Glennon and Dukat identified terminal amine size and α-substituent chain length as the principal SAR determinants for cathinone transporter selectivitysupported

Key structural features: nature of terminal amine, size of alpha-substituent. These features determine whether compound acts as releasing agent or reuptake inhibitor, and transporter selectivity. 7854_2016_41

Extension of the N-alkyl chain from methyl to ethyl tends to augment SERT potency relative to DAT/NET while reducing releasing efficacy, shifting the compound toward a pure uptake inhibitor profilesupported

Para-chloro substitution or increased N-alkyl chain length augmented SERT potency. Combined para-chloro + N-ethyl substitutions reduced releasing at NET/DAT. j.neuropharm.2023.109827

Kolaczynska et al. demonstrated that both N-ethyl substitution and longer α-chains enhance DAT/NET inhibition potency in the cathinone series.supported

Extension of alkyl chain enhances NET/DAT inhibition potency. ijms22158277

Claim in effects-overview — not_supportednot supportedworking →